Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 20 Jun 2023 |
| Genmab A/S has published its Articles of Association | 19 Jun 2023 |
| Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023 | 9 Jun 2023 |
| Grant of Restricted Stock Units and Warrants to Employees in Genmab | 8 Jun 2023 |
| Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference | 6 Jun 2023 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 1 Jun 2023 |